Vaxart (OTCMKTS:VXRT) Stock Crosses Below Two Hundred Day Moving Average – Here’s What Happened

Vaxart, Inc. (OTCMKTS:VXRT) passed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $0.58 and traded as low as $0.58. Vaxart shares last traded at $0.6001, with a volume of 682,120 shares changing hands.

Vaxart Stock Down 3.2%

The company’s 50-day moving average price is $0.68 and its 200-day moving average price is $0.58. The firm has a market cap of $145.25 million, a price-to-earnings ratio of 4.00 and a beta of 1.10.

Vaxart (OTCMKTS:VXRT) last announced its earnings results on Thursday, May 7th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.02. Vaxart had a net margin of 14.51% and a return on equity of 61.43%. The business had revenue of $39.23 million for the quarter, compared to analyst estimates of $50.50 million.

Hedge Funds Weigh In On Vaxart

Institutional investors and hedge funds have recently bought and sold shares of the company. Marshall Wace LLP purchased a new stake in shares of Vaxart in the 2nd quarter valued at approximately $794,000. Jones Financial Companies Lllp raised its stake in shares of Vaxart by 276,364.7% in the 1st quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company’s stock valued at $196,000 after acquiring an additional 478,111 shares during the period. Raymond James Financial Inc. raised its stake in shares of Vaxart by 16.9% in the 2nd quarter. Raymond James Financial Inc. now owns 236,166 shares of the biotechnology company’s stock valued at $107,000 after acquiring an additional 34,075 shares during the period. Invesco Ltd. raised its stake in shares of Vaxart by 93.1% in the 1st quarter. Invesco Ltd. now owns 146,366 shares of the biotechnology company’s stock valued at $60,000 after acquiring an additional 70,568 shares during the period. Finally, Creative Planning purchased a new stake in shares of Vaxart in the 2nd quarter valued at approximately $33,000. 18.05% of the stock is currently owned by institutional investors and hedge funds.

Vaxart Company Profile

Vaxart, Inc is a clinical-stage biotechnology company pioneering the development of oral recombinant vaccines administered in tablet form. Leveraging a proprietary, room-temperature-stable platform, the company aims to simplify vaccine delivery while eliciting both systemic and mucosal immune responses. Its technology is based on the replication-defective adenovirus vector system, which encodes target antigens designed to protect against a range of infectious diseases without the need for injections or cold-chain logistics.

The company’s pipeline includes multiple vaccine candidates in various stages of development.